NUWE · Nuwellis, Inc.
$2.85
-0.09 (-3.06%)
At close · Jul 17
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, including continued operating losses, negative cash flows from operations, an accumulated deficit of $320.9 million, and the need for additional capital to fund ongoing operations and growth initiatives (including the integration of the Rendiatech acquisition), raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the date these financial statements are issued. While management’s plans, including recent financing activities, cost discipline initiatives, and contingency measures, are intended to address these conditions, such plans do not alleviate the substantial doubt.”View the 10-Q filed May 15, 2026
Market Cap
$7.64M
Shares
2,680,752
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.85
Open$2.90
Day$2.77–2.97
52W$2.73–577.50
Avg vol 30d213K
Short int76K · 2.8% float · 1.0d
Short vol59%
Last earningsMay 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−95%
below
Price vs 50-day avg
−82%
below
RSI (14)
19
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−42%
trailing
6-month return
−96%
trailing
YTD return
−95%
this year
Relative strength
−104%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $60 — 200d above 50d
Institutional flow
Distributing
-20% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.84% of float · ▼ -50.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 1-yr range
Squeeze score
42
elevated · 0–100
Fundamentals
Revenue growth
−5%
Y/Y
Gross margin
62%
contracting
EPS growth
+93%
Y/Y
Free cash flow
$-10.9M
Valuation
P/E 0.1
below peers
Balance sheet
$2.8M
net debt
Quant / Vol
risk profile
Volatility
148%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
32.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−95%
Bearish
Price vs 50-day avg
−82%
Bearish
RSI (14)
19
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $15 › 200d $60 — 200d above 50d
Institutional flow
Distributing
-20% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.84% of float · ▼ -50.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $3
Now $3 · 0%
52-wk high $578
vs 200-day avg -95%
vs 50-day avg -82%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| circuit sales growth | 15% | Q1 2026 call | — |
| console sales | 15 | Q1 2026 call | — |
| pediatric centers | 47 | Q1 2026 call | — |
| pediatric revenue share of total U.S. revenue | 50% | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NUWE
this stock
Nuwellis, Inc.
|
$7.64M | -95.3% | -5.4% | 0.1 | 2.8% |
|
ABT
Abbott Laboratories
|
$175.37B | -19.2% | +5.7% | 28.2 | 1.3% |
|
SYK
Stryker Corp
|
$122.63B | -8.7% | +11.2% | 37.0 | 1.8% |
|
MDT
Medtronic plc
|
$106.50B | -12.7% | +8.4% | 22.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.44B | -53.8% | +5.5% | 18.4 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NUWE | -6.3% | -41.8% | -96.3% | -6.6% | -95.3% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -4.7% | -42.2% | -104.2% | -6.1% | -104.3% |